Source: International Congress 2014 – Update on lung cancer biology for clinicians



Rating:

Share or cite this content

Citations should be made in the following way:
L. Paz-Ares (Sevilla, Spain). ALK- and ROS-1-inhibition: a relevant treatment strategy for lung cancer?. International Congress 2014 – Update on lung cancer biology for clinicians

Member's Comments

No comment yet.

Related content which might interest you: Lung cancer: does age affect treatment strategy? Source: Eur Respir Mon; 2009: 43:306–326 Year: 2009 First-line treatment of EGFR-mutated nonsmall cell lung cancer: critical review on study methodology Source: Eur Respir Rev 2014; 23: 92-105 Year: 2014 Biomarkers for non-small cell lung cancer (NSCLC) treatment: examples and unmet needs, a clinical perspective Source: International Congress 2014 – From bench to bedside: biomarkers and biobanking for lung cancer in 2014 Year: 2014 Clonality of multifocal nonsmall cell lung cancer: implications for staging and therapy Source: Eur Respir J 2012; 39: 1437-1442 Year: 2012 Radiotherapy in small cell lung cancer: patient options Source: Virtual Congress 2020 – Thoracic oncology Year: 2020 Impact of COPD on prognosis of lung cancer: the prespective of immunotherapy treatment Source: Virtual Congress 2021 – Therapy of lung cancer Year: 2021 Should there be a specific management for large cell neuroendocrine carcinoma? Source: Annual Congress 2005 - Neuroendocrine tumours of the lung Year: 2005 Treatment of extensive-stage small cell lung carcinoma: current status and future prospects Source: Eur Respir J 2010; 35: 202-215 Year: 2010 Immunotherapy for nonsmall cell lung cancer: a new therapeutic algorithm Source: Eur Respir J, 55 (2) 1901907; 10.1183/13993003.01907-2019 Year: 2020 COX-2 as prognostic factor in lung cancer: systematic review of the literature with meta-analysis Source: Annual Congress 2005 - Prognostic factors in lung cancer Year: 2005 An abnormal CT, now what: issues in the diagnosis and management of a patient with a potential lung cancer Source: Annual Congress 2006 - MP11 - An abnormal CT, now what: issues in the diagnosis and management of a patient with a potential lung cancer Year: 2006 Challenges in the management of SCLC Part 2: Extensive disease, prophylaxis/treatment of brain metastases Source: ERS webinar 2021: Challenges in the management of SCLC Part 2: Extensive disease, prophylaxis/treatment of brain metastases Year: 2021 Customising chemotherapy in advanced nonsmall cell lung cancer: daily practice and perspectives Source: Eur Respir Rev 2011; 20: 45-52 Year: 2011 Should patients with metastatic NSCLC and poor performance status be treated by chemotherapy? Source: Annual Congress 2007 - Treatment of metastatic nonsmall cell lung cancer in the era of targeted therapies Year: 2007 Surgery for elderly early-stage non-small cell lung cancer: less or more? Source: International Congress 2019 – All aspects of general thoracic surgery Year: 2019 Why can initial treatment of localised lung cancer fail? Source: Annual Congress 2007 - Recurrence of lung cancer following resection with curative intent Year: 2007 Targeted therapies for lung cancer: how did the game begin? Source: Breathe 2016; 12: 177-179 Year: 2016 Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight Source: ERS webinar 2021: Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight Year: 2021